



Attorney Docket No.: 4409.214-US

TECH CENTER 1600/2900 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jonassen et al.

Serial No.: 09/772,607

Group Art Unit: 1653

Filed: January 30, 2001

Examiner: Kam, Chin Min

Confirmation No: 2082

For: Peptide Derivatives

BEST AVAILABLE COPY

PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))

Commissioner for Patents
Washington, DC 20231

Sir:

It is respectfully requested that the time for response to the Office Action dated May 31, 2002, be extended for a period of 3 months from August 31, 2002, to November 30, 2002. Applicant(s) hereby petition(s) for such extension of time.

In the event that an additional extension of time is required, Applicant(s) hereby petition(s) for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

Please charge the required fee, estimated to be \$920, with this application and to credit any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 27, 2002

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800



23650

PATENT TRADEMARK OFFICE

12/10/2002 CDHAI1 00000136 141447 09772607

01 FC:1253

920.00 CH